Region
Featured experience
Meituan $717 million acquisition of Dingdong’s China business
We are advising Meituan on the transaction
MiniMax Group HK$4.8 billion IPO
We advised MiniMax Group on its IPO and HKEX listing
Baidu CNY4.4 billion notes offering
The investment-grade notes are due 2029
Tencent €1.16 billion investment in new Ubisoft subsidiary
We are advising Tencent on the transaction
DFZQ $300 million bonds offering
The investment-grade bonds are due 2025
Total victory in securities class actions related to COVID-19 pandemic
We secured dismissals of state and federal securities cases on behalf of Chinese audio platform Lizhi
InnoCare Pharma RMB2.9 billion Shanghai IPO
This is the largest A-share listing by an overseas-listed biotechnology company in 2022 so far
Tencent Music Entertainment Group secondary listing
We advised Tencent Music Entertainment Group on its secondary listing by way of introduction on the HKEX
Interra Acquisition HK$1 billion IPO
We advised the SPAC on its IPO and HKEX listing
Tencent €300 million investment in Ubisoft
We are advising Tencent on the transaction
Biocytogen HK$549 million IPO
We advised Biocytogen on its IPO and HKEX listing
Red Star Macalline Group $249.7 million credit enhanced bonds offering
We advised the issuer on the credit enhanced bonds offering
Esco Aster spinoff transactions
We are advising Esco Lifesciences on the spinoff
InSilico Medicine $35 million Series D2 financing
We are advising InSilico Medicine on the financing